Signaling Pathway News and Research

RSS

Abbott signs licensing agreement with Pierre Fabre SA to develop and commercialize cancer antibody h224G11

Abbott announced today an exclusive worldwide licensing agreement with Pierre Fabre SA to develop and commercialize h224G11, a pre-clinical monoclonal antibody identified at the Centre d'Immunologie Pierre Fabre (CIPF) in France and targeting the cMet receptor for the treatment of cancer.

1 Feb 2010

Blood flowing with force protects against dangerous clogs in blood vessels

It is second nature for most of us that exercise protects against heart attack and stroke, but researchers have spent 30 years unraveling the biochemistry behind the idea. One answer first offered by researchers at the University of Rochester Medical Center is that athletic hearts push blood through arteries with greater force, which alone triggers reactions that protect against dangerous clogs in blood vessels.

29 Jan 2010

UT-Battelle exclusively licenses patents on inventions based on Nell-1 gene

In a major step toward commercialization of a promising therapeutic treatment, Oak Ridge National Laboratory contractor UT-Battelle announced at a signing ceremony here today that it has exclusively licensed patents on inventions based on the Nell-1 gene to NellOne Therapeutics, Inc. (NellOne), a company spun out of research performed at the Department of Energy laboratory.

29 Jan 2010

Patients with epilepsy who take Ginkgo herbal medicines face increased risk of seizures

Restrictions should be placed on the use of Ginkgo biloba (G. biloba) - a top-selling herbal remedy - because of growing scientific evidence that Ginkgo may increase the risk of seizures in people with epilepsy and could reduce the effectiveness of anti-seizure drugs, a new report concludes.

28 Jan 2010

Researchers challenge prevailing belief about role of protein in abnormal cell proliferation

In a study to be published this week, a research team is challenging a prevailing belief about the behavior of a human protein linked to the formation of cancer, possibly breathing new life into the search for therapies that will inhibit that protein from "turning on" genes involved in abnormal cell proliferation.

27 Jan 2010

Findings may yield novel therapeutic strategies for late-stage breast cancer

Researchers from the Boston University School of Medicine (BUSM) have determined how the TGFβ-Smad signaling pathway, which is over activated in late-stage cancers, is responsible for the "epigenetic memory" that maintains unique patterns of regulatory DNA hypermethylation causing silencing of critical genes that facilitate breast cancer progression.

25 Jan 2010

ACS Chemical Biology report supports zebrafish for drug development

By combining the tools of medicinal chemistry and zebrafish biology, a team of Vanderbilt investigators has identified compounds that may offer therapeutic leads for bone-related diseases and cancer.

22 Jan 2010

The American Journal of Pathology: Highlights from February 2010 issue

A group led by Dr. Peter Lloyd Jones at the University of Dundee, Dundee, Scotland; the University of Colorado Denver, Aurora, CO; and the University of Pennsylvania, Philadelphia, PA has demonstrated that tenascin-C affects proto-oncogene function in breast cancer. Their report can be found in the February 2010 issue of The American Journal of Pathology.

22 Jan 2010

Scientists manipulate and expand the number of stem/progenitor cells

Scientists at Fred Hutchinson Cancer Research Center have cleared a major technical hurdle to making umbilical-cord-blood transplants a more widely-used method for treating leukemia and other blood cancers.

18 Jan 2010

HHMI: Distinct cancer-causing mutations in neighboring cells can cooperate to produce tumors

According to modern biology textbooks, a single genetic mutation is rarely enough to cause cancer. It is generally thought that cells must accumulate a series of mutations that work together to trigger tumor development.

18 Jan 2010

M. D. Anderson researchers discover mechanism that helps glioblastomas evade immune attack

Cancer-initiating cells that launch glioblastoma multiforme, the most lethal type of brain tumor, also suppress an immune system attack on the disease, scientists from The University of Texas M. D. Anderson Cancer Center report in a paper featured on the cover of the Jan. 15 issue of Clinical Cancer Research.

18 Jan 2010

Treatment for chronic hepatitis C with pegylated-interferon and ribavirin proves effective

The current standard treatment for chronic hepatitis C with pegylated-interferon (PEG-IFN) and ribavirin is effective in approximately 50%-60% of patients, so that a substantial proportion of patients remain unresponsive.

18 Jan 2010

Phase I clinical trial for Intellikine's INK128 inhibitor initiated

Intellikine, Inc. has initiated a Phase I clinical trial for its targeted anticancer drug INK128, a novel orally-available small molecule inhibitor of both the TORC1 and TORC2 complexes, key components of the PI3K/mTOR signaling pathway.

6 Jan 2010

TSC proteins regulate Notch activity

Two independent teams of researchers have identified a role for enhanced activation of the signaling protein Notch in tumors characterized by inactivation of either the TSC1 or the TSC2 protein. As indicated by Warren Pear, at the University of Pennsylvania, Philadelphia, in an accompanying commentary, these data provide a rationale for testing whether Notch inhibitors are of benefit to those with TSC-associated tumors.

29 Dec 2009

Gene's role in immune system may suggest new treatments for childhood asthma

Pediatric researchers have identified a novel gene involved in childhood asthma, in one of the largest gene studies to date of the common respiratory disease. Because the gene, called DENND1B, affects cells and signaling molecules thought to be instrumental in the immune system overreaction that occurs in asthma, the discovery may have singled out an important target for new treatments.

23 Dec 2009

National MS Society calls for grant applications to examine the impact of CCSVI hypothesis

2009 saw exciting research progress, unprecedented opportunities on the horizon, and more scientists than ever working on resolving important questions. Despite the year's economic and financial challenges, the National Multiple Sclerosis Society continues to propel research forward to end MS. In 2009 the Society provided over $33.5 million to support 345 new and ongoing projects in its research portfolio, plus $1.5 million for Fast Forward, the Society's drug development subsidiary which continues to attract new funding streams.

23 Dec 2009

Comprehensive approaches to understand the interaction of H1N1 strains with human cells

Scientists have generated hundreds of new leads in the fight against the H1N1 flu pandemic, according to two new studies published online December 17th in the journal Cell, a Cell Press publication.

18 Dec 2009

CTRC-AACR San Antonio Breast Cancer Symposium presents new data on emerging breast cancer therapies

Breast cancer continues to be a dynamic field of research, and the CTRC-AACR San Antonio Breast Cancer Symposium, now in its 32nd year, is the premier destination to present new data on emerging therapies.

14 Dec 2009

Findings from three studies using bioTheranostics' breast cancer molecular test reported

bioTheranostics, a bioMerieux company that develops innovative oncology diagnostic tests to drive personalized treatment, reported today findings from three studies using the company's breast cancer molecular test.

14 Dec 2009

Mouse study shows delaying the ageing process may offer protection against Alzheimer’s disease

Aging is the single greatest risk factor for Alzheimer's disease. In their latest study, researchers at the Salk Institute for Biological Studies found that simply slowing the aging process in mice prone to develop Alzheimer's disease prevented their brains from turning into a neuronal wasteland.

10 Dec 2009

Signaling Pathway News and Research

Abbott signs licensing agreement with Pierre Fabre SA to develop and commercialize cancer antibody h224G11

Blood flowing with force protects against dangerous clogs in blood vessels

UT-Battelle exclusively licenses patents on inventions based on Nell-1 gene

Patients with epilepsy who take Ginkgo herbal medicines face increased risk of seizures

Researchers challenge prevailing belief about role of protein in abnormal cell proliferation

Findings may yield novel therapeutic strategies for late-stage breast cancer

ACS Chemical Biology report supports zebrafish for drug development

The American Journal of Pathology: Highlights from February 2010 issue

Scientists manipulate and expand the number of stem/progenitor cells

HHMI: Distinct cancer-causing mutations in neighboring cells can cooperate to produce tumors

M. D. Anderson researchers discover mechanism that helps glioblastomas evade immune attack

Treatment for chronic hepatitis C with pegylated-interferon and ribavirin proves effective

Phase I clinical trial for Intellikine's INK128 inhibitor initiated

TSC proteins regulate Notch activity

Gene's role in immune system may suggest new treatments for childhood asthma

National MS Society calls for grant applications to examine the impact of CCSVI hypothesis

Comprehensive approaches to understand the interaction of H1N1 strains with human cells

CTRC-AACR San Antonio Breast Cancer Symposium presents new data on emerging breast cancer therapies

Findings from three studies using bioTheranostics' breast cancer molecular test reported

Mouse study shows delaying the ageing process may offer protection against Alzheimer’s disease

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News